Amsbio announce StemFit™ Basic05, a next-generation, animal origin-free medium designed for scalable human pluripotent stem cell (hPSC) manufacturing.

Compatible with both 2D adherent and 3D suspension culture, this unique cell culture medium enables a streamlined workflow from cell expansion to process scale-up using a single medium. The use of a single medium across culture modes minimizes the need for process re-development and optimization traditionally associated with media changes.

Beneficially, pluripotent stem cells cultured in StemFit™ Basic05 also retain their differentiation capability and have been confirmed to be capable of differentiation directly from 3D aggregates.

For labs looking to implement stable and scalable suspension culture and scalable processes – high cell viability and uniform spheroid formation are vital prerequisites. StemFit™ Basic05 has been demonstrated to reliably deliver high cell viability and uniform spheroid formation across multiple human iPSC lines, along with maintenance of a normal karyotype.  Offering robust and highly reproducible uniform spheroid formation – StemFit™ Basic05 is the perfect process development medium that also reduces process complexity and development burden.

StemFit™ Basic05 supports flexible culture scheduling, with comparable cell expansion even when weekend feeding was omitted.

For further information please visit https://www.amsbio.com/stemfit-stem-cell-culture/

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem cell platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology.